HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice

Simple item page
dc.contributor.authorPillay, Sirikaen_ZA
dc.contributor.authorShephard, Eniden_ZA
dc.contributor.authorMeyers, Annen_ZA
dc.contributor.authorWilliamson, Anna-Liseen_ZA
dc.contributor.authorRybicki, Edward Pen_ZA
dc.date.accessioned2015-11-11T12:00:12Z
dc.date.available2015-11-11T12:00:12Z
dc.date.issued2010en_ZA
dc.description.abstractSeveral approaches have been explored to eradicate HIV; however, a multigene vaccine appears to be the best option, given their proven potential to elicit broad, effective responses in animal models. The Pr55Gag protein is an excellent vaccine candidate in its own right, given that it can assemble into large, enveloped, virus-like particles (VLPs) which are highly immunogenic, and can moreover be used as a scaffold for the presentation of other large non-structural HIV antigens. In this study, we evaluated the potential of two novel chimaeric HIV-1 Pr55Gag-based VLP constructs - C-terminal fusions with reverse transcriptase and a Tat::Nef fusion protein, designated GagRT and GagTN respectively - to enhance a cellular response in mice when used as boost components in two types of heterologous prime-boost vaccine strategies. A vaccine regimen consisting of a DNA prime and chimaeric HIV-1 VLP boosts in mice induced strong, broad cellular immune responses at an optimum dose of 100 ng VLPs. The enhanced cellular responses induced by the DNA prime-VLP boost were two- to three-fold greater than two DNA vaccinations. Moreover, a mixture of GagRT and GagTN VLPs also boosted antigen-specific CD8+ and CD4+ T-cell responses, while VLP vaccinations only induced predominantly robust Gag CD4+ T-cell responses. The results demonstrate the promising potential of these chimaeric VLPs as vaccine candidates against HIV-1.en_ZA
dc.identifier.apacitationPillay, S., Shephard, E., Meyers, A., Williamson, A., & Rybicki, E. P. (2010). HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice. <i>Journal of Immune Based Therapies and Vaccines</i>, http://hdl.handle.net/11427/14884en_ZA
dc.identifier.chicagocitationPillay, Sirika, Enid Shephard, Ann Meyers, Anna-Lise Williamson, and Edward P Rybicki "HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice." <i>Journal of Immune Based Therapies and Vaccines</i> (2010) http://hdl.handle.net/11427/14884en_ZA
dc.identifier.citationPillay, S., Shephard, E. G., Meyers, A. E., Williamson, A. L., & Rybicki, E. P. (2010). HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice. Journal of immune based therapies and vaccines, 8(1), 7.en_ZA
dc.identifier.ris TY - Journal Article AU - Pillay, Sirika AU - Shephard, Enid AU - Meyers, Ann AU - Williamson, Anna-Lise AU - Rybicki, Edward P AB - Several approaches have been explored to eradicate HIV; however, a multigene vaccine appears to be the best option, given their proven potential to elicit broad, effective responses in animal models. The Pr55Gag protein is an excellent vaccine candidate in its own right, given that it can assemble into large, enveloped, virus-like particles (VLPs) which are highly immunogenic, and can moreover be used as a scaffold for the presentation of other large non-structural HIV antigens. In this study, we evaluated the potential of two novel chimaeric HIV-1 Pr55Gag-based VLP constructs - C-terminal fusions with reverse transcriptase and a Tat::Nef fusion protein, designated GagRT and GagTN respectively - to enhance a cellular response in mice when used as boost components in two types of heterologous prime-boost vaccine strategies. A vaccine regimen consisting of a DNA prime and chimaeric HIV-1 VLP boosts in mice induced strong, broad cellular immune responses at an optimum dose of 100 ng VLPs. The enhanced cellular responses induced by the DNA prime-VLP boost were two- to three-fold greater than two DNA vaccinations. Moreover, a mixture of GagRT and GagTN VLPs also boosted antigen-specific CD8+ and CD4+ T-cell responses, while VLP vaccinations only induced predominantly robust Gag CD4+ T-cell responses. The results demonstrate the promising potential of these chimaeric VLPs as vaccine candidates against HIV-1. DA - 2010 DB - OpenUCT DO - 10.1186/1476-8518-8-7 DP - University of Cape Town J1 - Journal of Immune Based Therapies and Vaccines LK - https://open.uct.ac.za PB - University of Cape Town PY - 2010 T1 - HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice TI - HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice UR - http://hdl.handle.net/11427/14884 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/14884
dc.identifier.urihttp://dx.doi.org/10.1186/1476-8518-8-7
dc.identifier.vancouvercitationPillay S, Shephard E, Meyers A, Williamson A, Rybicki EP. HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice. Journal of Immune Based Therapies and Vaccines. 2010; http://hdl.handle.net/11427/14884.en_ZA
dc.language.isoengen_ZA
dc.publisherBioMed Central Ltden_ZA
dc.publisher.departmentDepartment of Molecular and Cell Biologyen_ZA
dc.publisher.facultyFaculty of Scienceen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution Licenseen_ZA
dc.rights.holder2010 Pillay et al; licensee BioMed Central Ltd.en_ZA
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_ZA
dc.sourceJournal of Immune Based Therapies and Vaccinesen_ZA
dc.source.urihttp://www.jibtherapies.com/en_ZA
dc.subject.otherHIVen_ZA
dc.subject.otherAntibodiesen_ZA
dc.subject.otherImmune Responsesen_ZA
dc.subject.otherMiceen_ZA
dc.titleHIV-1 sub-type C chimaeric VLPs boost cellular immune responses in miceen_ZA
dc.typeJournal Articleen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Pillay_HIV1_subtype_C_chimaeric_VLPs_2010.pdf
Size:
913.33 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles